Wide Ranks

ALMS

Alumis Inc.

9.72

Top Statistics
Market Cap 528 M Forward PE -1.26 Revenue Growth 0.00 %
Current Ratio 11.26 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.8280 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 361 M Total Cash Per Share 6.65 Total Debt 31 M
Total Debt To Equity 8.93 Current Ratio 11.26 Book Value Per Share 6.40
All Measures
Short Ratio 2737.00 % Message Board Id finmb_705657695 Shares Short Prior Month 2 M
City South San Francisco Uuid 7bc517b3-133f-3f7c-b6dd-349f2d478c1b Previous Close 9.40
First Trade Date Epoch Utc 1 B Book Value 6.40 Total Debt 31 M
Volume 38427 Price To Book 1.52 Fifty Two Week Low 8.22
Total Cash Per Share 6.65 Shares Short Previous Month Date 1 B Target Median Price 29.00
Max Age 86400 Recommendation Mean 1.33 Sand P52 Week Change 0.3133
Target Mean Price 30.00 Net Income To Common -238774000 Ask 9.82
Short Percent Of Float 0.0594 Implied Shares Outstanding 54 M Last Fiscal Year End 1 B
Trailing Peg Ratio None Average Daily Volume10 Day 137520 Average Volume10days 137520
Total Cash 361 M Next Fiscal Year End 1 B Held Percent Insiders 0.0120
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 9.40 Target Low Price 25.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 10.94 Open 9.52 Dividend Yield 0.00 %
State CA Time Zone Short Name EST Trailing Eps -4.39
Day Low 9.44 Address1 280 East Grand Avenue Shares Outstanding 47 M
Price Hint 2 Target High Price 38.00 Website https://www.alumis.com
52 Week Change -0.2692 Average Volume 148914 Forward Eps -6.20
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1079.70 %
Is_sp_500 False Regular Market Day High 9.91 Profit Margins 0.00 %
Debt To Equity 8.93 Fifty Two Week High 13.53 Day High 9.91
Shares Short 2 M Regular Market Open 9.52 Industry Key biotechnology
Bid 9.56 Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0407 Currency USD Time Zone Full Name America/New_York
Market Cap 528 M Is_nasdaq_100 False Zip 94080
Quote Type EQUITY Industry Biotechnology Long Name Alumis Inc.
Regular Market Day Low 9.44 Held Percent Institutions 0.7464 Current Price 9.72
Enterprise To Ebitda -0.8280 Financial Currency USD Current Ratio 11.26
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 14 M Two Hundred Day Average 11.64 Enterprise Value 198 M
Forward PE -1.26 Regular Market Volume 38427 Ebitda -239060000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.

It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases.

The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.

The company was incorporated in 2021 and is headquartered in South San Francisco, California.